Cerevel plots first late-stage move as Pfizer drug comes through in PhII Parkinson's trial
One of the drugs that Cerevel Therapeutics has picked up from Pfizer’s neuroscience pipeline has shown promise in a Phase II trial, paving the way …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
